| Literature DB >> 31776362 |
Yu Ah Hong1, Hye Eun Yoon1, Bum Soon Choi1, Seok Joon Shin1, Yong-Soo Kim1, So Young Lee2, Sang-Ho Lee3, Su Hyun Kim4, Eun Young Lee5, Sug Kyun Shin6, Young Joo Kwon7, Jeong Ho Kim1, Yoon Kyung Chang1, Suk Young Kim1, Ji Eun Kim7, Shin Young Ahn7, Gang Jee Ko8.
Abstract
Adequate fluid management plays an important role in decreasing cardiovascular risk in peritoneal dialysis (PD) patients. We evaluated whether strict volume control monitored by bioimpedance spectroscopy (BIS) affects cardiac function in PD patients. This study is a secondary analysis of a multicentre, prospective, randomized, controlled trial. Fluid overload was assessed by the average overhydration/extracellular water (OH/ECW) at baseline, 6 months and 12 months. Patients were categorized as time-averaged overhydrated (TA-OH/ECW ≥15%) or normohydrated (TA-OH/ECW <15%), and echocardiographic parameters were compared between groups. Among a total of 151 patients, 120 patients exhibited time-averaged normohydration. Time-averaged overhydrated patients had a significantly higher left atrial (LA) diameter and E/e' ratio and a lower left ventricular (LV) ejection fraction at 12 months than time-averaged normohydrated patients. LA diameter, end-systolic volume and end-diastolic volume were decreased at 12 months compared to baseline in time-averaged normohydrated patients only. TA-OH/ECW was independently associated with ejection fraction at 12 months (β = -0.190; p = 0.010). TA-OH/ECW, but not OH/ECW at 12 months, was an independent risk factor for LV dysfunction (odds ratio 4.020 [95% confidence interval 1.285-12.573]). Overhydration status based on repeated BIS measurements is an independent predictor of LV systolic function in PD patients.Entities:
Mesh:
Year: 2019 PMID: 31776362 PMCID: PMC6881363 DOI: 10.1038/s41598-019-53792-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Study design and flow chart of study participants.
Figure 2Distribution of average relative overhydration over one year (TA-OH/ECW) in 151 PD patients, ranging between −14% and 35% (8.7 ± 7.9%; median 8.6%).
The comparison of clinical and laboratory parameters between study groups at baseline and the end of study.
| Baseline | 12 months | |||||
|---|---|---|---|---|---|---|
| TA-OH/ECW <15% | TA-OH/ECW ≥15% | p value | TA-OH/ECW <15% | TA-OH/ECW 15% | p value | |
| Age | 53.5 ± 12.8 | 55.8 ± 9.0 | 0.342 | |||
| Sex (male) (%) | 66 (55.0) | 16 (51.6) | 0.736 | |||
| BMI (Kg/m2) | 24.5 ± 3.4 | 23.9 ± 4.0 | 0.419 | |||
| DM (%) | 43 (35.8) | 26 (83.9) | <0.001 | |||
| Hypertension (%) | 96 (80.0) | 26 (83.9) | 0.626 | |||
| Cause of ESRD (%) | 0.001 | |||||
| DM (%) | 38 (31.7) | 22 (71.0) | ||||
| Hypertension (%) | 39 (32.5) | 3 (9.7) | ||||
| CGN (%) | 12 (10.0) | 2 (6.5) | ||||
| Others/Unknown (%) | 31 (25.8) | 4 (12.9) | ||||
| PD duration (months) | 11.8 ± 21.0 | 11.3 ± 19.0 | 0.909 | |||
| D/P Cr at 4-hr PET | 0.61 ± 0.12 | 0.67 ± 0.16 | 0.037 | 0.60 ± 0.11 | 0.66 ± 0.13 | 0.024 |
| No. of anti-hypertensive agents | 2.0 ± 1.5 | 2.7 ± 1.6 | 0.025 | 1.3 ± 1.5 | 2.0 ± 1.4 | 0.008 |
| Urine output (L/day) | 1.00 ± 0.47 | 1.24 ± 1.71 | 0.444 | 0.83 ± 0.48 | 0.81 ± 0.63 | 0.855 |
| Systolic BP (mmHg) | 132.1 ± 25.6 | 139.7 ± 24.8 | 0.143 | 133.6 ± 19.7 | 142.0 ± 25.8 | 0.100 |
| Diastolic BP (mmHg) | 79.4 ± 13.2 | 76.2 ± 11.0 | 0.220 | 79.7 ± 10.7 | 77. 8 ± 11.0 | 0.377 |
| Pulse pressure (mmHg) | 52.7 ± 19.0 | 63.5 ± 19.3 | 0.006 | 53.9 ± 15.4 | 64.2 ± 18.9 | 0.002 |
| Laboratory findings | ||||||
| Hemoglobin (g/dL) | 11.1 ± 1.2 | 10.8 ± 1.5 | 0.241 | 11.1 ± 1.6 | 10.3 ± 1.3 | 0.029 |
| Glucose (mg/dL) | 122.1 ± 56.7 | 159.4 ± 89.7 | 0.034 | 128.1 ± 70.1 | 153.2 ± 77.6 | 0.084 |
| Serum Creatinine (mg/dL) | 8.1 ± 2.7 | 7.5 ± 3.1 | 0.289 | 9.5 ± 3.4 | 9.1 ± 3.3 | 0.471 |
| Serum Albumin (g/dL) | 3.7 ± 0.4 | 3.3 ± 0.5 | <0.001 | 3.7 ± 0.4 | 3.4 ± 0.5 | <0.001 |
| Echocardiographic parameters | ||||||
| LA diameter (mm) | 38.2 ± 6.2 | 40.8 ± 7.2 | 0.052 | 36.7 ± 6.1 | 39.4 ± 6.7 | 0.036 |
| LA volume (ml) | 48.3 ± 20.8 | 51.5 ± 19.4 | 0.628 | 45.8 ± 22.9 | 49.4 ± 22.4 | 0.477 |
| LVESd (mm) | 32.9 ± 9.7 | 34.1 ± 6.9 | 0.512 | 31.6 ± 10.6 | 34.5 ± 9.4 | 0.165 |
| LVEDd (mm) | 50.2 ± 11.1 | 51.1 ± 9.5 | 0.676 | 48.7 ± 11.4 | 50.7 ± 8.5 | 0.359 |
| LV mass index (g/m2) | 128.6 ± 69.9 | 140.4 ± 61.9 | 0.395 | 121.1 ± 56.1 | 120.1 ± 46.9 | 0.926 |
| ESV (ml) | 38.5 ± 21.7 | 39.0 ± 18.6 | 0.904 | 32.2 ± 15.1 | 37.5 ± 18.6 | 0.107 |
| EDV (ml) | 101.8 ± 41.0 | 100.7 ± 35.8 | 0.885 | 83.9 ± 31.7 | 93.7 ± 34.7 | 0.145 |
| EF (%) | 62.8 ± 10.1 | 60.0 ± 7.8 | 0.155 | 61.6 ± 6.0 | 58.8 ± 7.9 | 0.034 |
| e′ velocity (cm/sec) | 5.7 ± 2.8 | 3.7 ± 2.9 | 0.001 | 5.9 ± 4.7 | 3.7 ± 2.6 | 0.010 |
| E/A | 0.88 ± 0.44 | 0.77 ± 0.22 | 0.047 | 0.88 ± 1.2 | 0.67 ± 0.14 | 0.347 |
| E/e′ | 11.7 ± 11.1 | 14.9 ± 6.0 | 0.131 | 10.3 ± 4.4 | 13.3 ± 5.0 | 0.004 |
*Abbreviation: BMI, body mass index; BP, blood pressure; CGN, chronic glomerulonephritis; DM, diabetes mellitus; D/P Cr, dialysate/peritoneal fluid creatinine ratio; e′, early diastolic mitral annular tissue velocity; E/A, early diastolic mitral inflow velocity/late diastolic mitral inflow velocity; EDV, end-diastolic volume; E/e′, early diastolic mitral inflow velocity/early diastolic mitral annular tissue velocity, EF, ejection fraction; ESRD, end-stage renal disease; ESV, end-systolic volume; LA, left atrial; LV, left ventricular; LVEDd, left ventricular end-diastolic diameter; LVESd, left ventricular end-systolic diameter; PD, peritoneal dialysis; PET, peritoneal equilibrium test.
Figure 3The comparison of changes of BIS Parameters between patients with TA-OH/ECW ≥15% and TA-OH/ECW <15% at baseline and the end of study. (A) Total body water, (B) Lean tissue mass, (C) Adipose tissue mass, (D) Extracellular water (ECW), and (E) Overhydration (OH).
Univariable and multivariable linear regressions for time-averaged relative hydration status and echocardiographic parameters at the end of study.
| Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|
| β | t | p value | β | t | p value | |
| 12-month LA diameter (mm) | 0.338 | 4.388 | <0.001 | 0.059 | 0.824 | 0.412 |
| 12-month LA volume (ml) | 0.197 | 2.165 | 0.032 | −0.059 | −0.729 | 0.468 |
| 12-month LVESd (mm) | 0.220 | 2.743 | 0.007 | 0.087 | 1.522 | 0.132 |
| 12-month LVEDd (mm) | 0.132 | 1.614 | 0.109 | — | — | — |
| 12-month LV mass index (g/m2) | 0.081 | 0.983 | 0.327 | — | — | — |
| 12-month ESV (mL) | 0.240 | 2.958 | 0.004 | −0.252 | −1.352 | 0.180 |
| 12-month EDV (mL) | 0.207 | 2.531 | 0.012 | 0.116 | 0.683 | 0.497 |
| 12-month EF (%) | −0.230 | −2.890 | 0.004 | −0.190 | −2.618 | 0.010 |
| 12-month e′ velocity (cm/sec) | −0.215 | −2.678 | 0.008 | −0.003 | −0.048 | 0.962 |
| 12-month E/A | −0.042 | −0.515 | 0.607 | — | — | — |
| 12-month E/e′ | 0.151 | 1.855 | 0.066 | −0.039 | −0.675 | −0.502 |
*Abbreviation: EDV, end-diastolic volume; E/e′, early diastolic mitral inflow velocity/early diastolic mitral annular tissue velocity; EF, ejection fraction; ESV, end-systolic volume; LA, left atrial; LV, left ventricular; LVEDd, left ventricular end-diastolic diameter; LVESd, left ventricular end-systolic diameter; TA-OH/ECW, time-averaged overhydration/extracellular water. The variables included in the multivariable linear regression model were age, PD duration, BMI, baseline OH, time-averaged pulse pressure, time-averaged hemoglobin, time-averaged albumin, time-averaged glucose, time-averaged D/P Creatinine at 4-hr PET and statistically significant variables among echocardiographic parameters in the univariable linear regression (p < 0.1). Dashes indicate that the variable did not enter the multivariable linear regression model.
The differences of echocardiographic parameters between baseline and the end of study in time-averaged overhydrated and normohydrated patients.
| TA-OH/ECW <15% (n = 120) | TA-OH/ECW ≥15% (n = 31) | |||||
|---|---|---|---|---|---|---|
| Baseline | 12 months | p value | Baseline | 12 months | p value | |
| LA diameter (mm) | 38.2 ± 6.2 | 36.7 ± 6.1 | 0.014 | 40.8 ± 7.2 | 39.4 ± 6.7 | 0.305 |
| LA volume (ml) | 48.3 ± 20.8 | 45.8 ± 22.9 | <0.001 | 51.5 ± 19.4 | 49.4 ± 22.4 | 0.001 |
| LVESd (mm) | 32.9 ± 9.7 | 31.6 ± 10.6 | 0.176 | 34.1 ± 6.9 | 34.5 ± 9.4 | 0.811 |
| LVEDd (mm) | 50.2 ± 11.1 | 48.7 ± 11.4 | 0.178 | 51.1 ± 9.5 | 50.7 ± 8.5 | 0.837 |
| LV mass index (g/m2) | 128.6 ± 69.9 | 121.1 ± 56.1 | 0.046 | 140.4 ± 61.9 | 120.1 ± 46.9 | 0.008 |
| ESV (ml) | 38.5 ± 21.7 | 32.2 ± 15.1 | <0.001 | 39.0 ± 18.6 | 37.5 ± 18.6 | 0.488 |
| EDV (ml) | 101.8 ± 41.0 | 83.9 ± 31.7 | <0.001 | 100.7 ± 35.8 | 93.7 ± 34.7 | 0.148 |
| EF (%) | 62.8 ± 10.1 | 61.6 ± 6.0 | 0.147 | 60.0 ± 7.8 | 58.8 ± 7.9 | 0.531 |
| e′ velocity (cm/sec) | 5.7 ± 2.8 | 5.9 ± 4.7 | 0.465 | 3.7 ± 2.9 | 3.7 ± 2.6 | 0.615 |
| E/A | 0.88 ± 0.44 | 0.88 ± 1.2 | 0.857 | 0.77 ± 0.22 | 0.67 ± 0.14 | 0.034 |
| E/e′ | 11.7 ± 11.1 | 10.3 ± 4.4 | 0.188 | 14.9 ± 6.0 | 13.3 ± 5.0 | 0.144 |
*Abbreviation: e′, early diastolic mitral annular tissue velocity; E/A, early diastolic mitral inflow velocity/late diastolic mitral inflow velocity; EDV, end-diastolic volume; E/e′, early diastolic mitral inflow velocity/early diastolic mitral annular tissue velocity; EF, ejection fraction; ESV, end-systolic volume; LA, left atrial; LV, left ventricular; LVEDd, left ventricular end-diastolic diameter; LVESd, left ventricular end-systolic diameter.
Univariable and multivariable logistic regression for the predictors of left ventricular systolic dysfunction at the end of study.
| Crude OR | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | |
| 12-month OH/ECW | ||||||
| <15% | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||
| ≥15% | 1.646 (0.582–4.654) | 0.347 | 0.736 (0.173–3.119) | 0.667 | 1.006 (0.213–4.738) | 0.994 |
| TA-OH/ECW | ||||||
| <15% | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||
| ≥15% | 2.863 (1.065–7.699) | 0.037 | 4.556 (1.520–13.657) | 0.007 | 4.020 (1.285–12.573) | 0.017 |
*Abbreviation: CI, confidence interval; OH/ECW, overhydration/extracellular water; OR, odds ratio; TA-OH/ECW, time-averaged overhydration/extracellular water.
*Multivariable logistic regression for 12-month OH/ECW was adjusted for Model 1: age, sex, BMI, presence of DM, cause of ESRD, PD duration, baseline OH, 12-month pulse pressure, 12-month D/P creatinine at 4-hr PET, 12-month hemoglobin, 12-month glucose, 12-month albumin, and Model 2: model 1 + 12-month LA diameter, 12-month LV mass index, and 12-month E/e′ ratio.
*Multivariable logistic regression for time-averaged OH/ECW was adjusted for Model 1: age, sex, BMI, presence of DM, cause of ESRD, PD duration, baseline OH, time-averaged pulse pressure, time-averaged D/P creatinine at 4-hr PET, time-averaged hemoglobin, time-averaged glucose, time-averaged albumin, and Model 2: model 1 + 12-month LA diameter, 12-month LV mass index, and 12-month E/e′ ratio.